Additional Utility of Pharmacogenomics (PGx) Panel Testing in a CYP2D6 Normal Metabolizer with a History of Breast Cancer

OBJECTIVE: To demonstrate the utility of pharmacogenomic (PGx) panel testing use versus single gene testing for a single indication. Panel testing may not only help further refine clinical decision making for the primary medical indication, it may uncover with one diagnostic test multiple PGx abnorm...

Descripción completa

Detalles Bibliográficos
Autor principal: Schuh, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of Minnesota Libraries Publishing 2019
Materias:
Case Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127095/
https://www.ncbi.nlm.nih.gov/pubmed/34007571
http://dx.doi.org/10.24926/iip.v10i3.2013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8127095/
https://www.ncbi.nlm.nih.gov/pubmed/34007571
http://dx.doi.org/10.24926/iip.v10i3.2013

Ejemplares similares